uniQure: 3-Year Huntington's Data Move AMT-130 From 'Promising' To 'Probable' (Rating Upgrade)

2025-10-28 13:55:02 ET

Overview

My last look at uniQure ( QURE ) was in April. I was focused on its gene therapy for Huntington’s disease, AMT-130. The company had just received the Breakthrough Therapy designation . Moreover, AMT-130’s preliminary data to date, although limited in numbers and duration, were probably supportive of accelerated approval. However, I expressed caution regarding AMT-130’s commercialization prospects given the lack of long-term efficacy/safety data, cost, and treatment logistics (e.g., its administration necessitates neurosurgery). I rated QURE a “cautious Hold in a barbell portfolio.”...

Read the full article on Seeking Alpha

For further details see: